Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 2/20 | 0.44 |
| ▸ | PREP | P48147 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 5/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 3/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1841848 | 1.00 | CASP3 (0.44) | CASP3PREPALDH1A1GAACTSK | |
| SCHEMBL12156504 | 1.00 | CASP3 (0.44) | CASP3PREPALDH1A1GAACTSK | |
| SCHEMBL1842398 | 0.91 | CASP3 (0.41) | CASP3PREPCTSKCASP1CTSB | |
| SCHEMBL13411399 | 0.91 | CASP3 (0.41) | CASP3PREPCTSKCASP1CTSB | |
| SCHEMBL13600777 | 0.89 | CASP3 (0.40) | CASP3PREPCTSKCASP1CTSB | |
| SCHEMBL13600773 | 0.88 | CASP3 (0.42) | CASP3PREPCTSKCASP1CTSB | |
| SCHEMBL2341992 | 0.88 | CASP3 (0.41) | CASP3PREPCTSKCASP1CTSB | |
| SCHEMBL12156505 | 0.88 | CASP3 (0.42) | CASP3PREPCTSKCASP1CTSB | |
| SCHEMBL1842401 | 0.87 | CASP3 (0.40) | CASP3PREPALDH1A1GAACTSK | |
| SCHEMBL1842404 | 0.87 | CASP3 (0.40) | CASP3PREPALDH1A1GAACTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250057958-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-02-20 | — | — | US | disclosed |
| WO-2023161881-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-08-31 | — | — | WO | disclosed |
| EP-2049477-B1 | MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY, CRYSTALLINE FORMS AND PROCESS | BRISTOL MYERS SQUIBB CO (US) | 2010-06-23 | — | — | EP | disclosed |
| EP-2194051-A1 | Process for preparing compounds useful as intermediates for the preparation of modulators of chemokine receptor activity | Bristol-Myers Squibb Company (US) | 2010-06-09 | — | — | EP | disclosed |
| EP-2184283-A1 | Process for preparing compounds useful as intermediates for the preparation of modulators of chemokine receptor activity | Bristol-Myers Squibb Company (US) | 2010-05-12 | — | — | EP | disclosed |
| US-20100113489-A1 | MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY, CRYSTALLINE FORMS AND PROCESS | BRISTOL-MYERS SQUIBB COMPANY | 2010-05-06 | — | — | US | disclosed |
| US-7671062-B2 | Modulators of chemokine receptor activity, crystalline forms and process | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-03-02 | — | — | US | disclosed |
| US-7629351-B2 | N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino) pyrrolidin-1-yl)cyclohexyl)acetamide and other modulators of chemokine receptor activity, crystalline forms and process | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-08 | — | — | US | disclosed |
| US-20080027084-A1 | MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY CRYSTALLINE FORMS AND PROCESS | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-31 | — | — | US | disclosed |
| US-20080027083-A1 | MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY CRYSTALLINE FORMS AND PROCESS | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250057958-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | CCR2, CCR1, CCRL2 | CASP3 845/4885PREP 2183/4885ALDH1A1 4466/4885 |
| US-20080027084-A1 | MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY CRYSTALLINE FORMS AND PROCESS | ACKR3, CCR1, CXCR1 | CASP3 1476/4885PREP 1946/4885ALDH1A1 1518/4885 |
| US-20080027083-A1 | MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY CRYSTALLINE FORMS AND PROCESS | ACKR3, CCR1, CCR2 | CASP3 1564/4885PREP 1642/4885ALDH1A1 1437/4885 |
| US-20100113489-A1 | MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY, CRYSTALLINE FORMS AND PROCESS | ACKR3, CCR1, CCR2 | CASP3 1702/4885PREP 1931/4885ALDH1A1 1192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.